Home › Pemphigus › NCT02753777

Autoimmune Blistering Diseases Study

Prevalence and Clinical Severity of Autoimmune Blistering Diseases

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Gender/Age: Males or females above 18 years old
* Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid
* Subjects able to give informed consent

Exclusion Criteria:

* Patients who are under age 18 years.
* Patients without pemphigus or pemphigoid diseases
* Penn employees
* Penn students
* Cognitively impaired persons

About the study

Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.

What is being tested

• Questionnaires (other)

Sponsor: University of Pennsylvania · Participants: 150 · Started: 2016-04

Contact the study team

• Victoria P Werth, MD · Phone: 215-615-2940
• Joyce Okawa, RN · Phone: 215-615-2960

Official record on ClinicalTrials.gov — NCT02753777

Locations in the U.S.

Conditions

• Pemphigus

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.